Celldex Accelerates Phase 3 Enrollment in Chronic Urticaria Trial
Event summary
- Celldex completed enrollment for Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) of barzolvolimab in chronic spontaneous urticaria (CSU).
- Enrollment was completed six months ahead of the initial guidance, involving 1,939 patients across 43 countries and over 500 sites.
- Topline data is expected in Q4 2026, with a Biologics License Application (BLA) planned for 2027.
- The Phase 3 program includes dosing regimens of barzolvolimab 150 mg every 4 weeks and 300 mg every 8 weeks, with placebo for a 52-week period, followed by re-randomization to active treatment.
The big picture
Celldex's accelerated enrollment underscores the significant unmet medical need in chronic spontaneous urticaria, a condition affecting millions globally. The rapid recruitment suggests a strong willingness among patients and physicians to explore novel treatment options beyond existing antihistamines and omalizumab. Success with barzolvolimab could establish Celldex as a key player in the immunology space, but hinges on demonstrating a clear clinical advantage and navigating the regulatory approval process.
What we're watching
- Clinical Efficacy
- The topline data release in Q4 2026 will be critical to assess barzolvolimab's efficacy compared to placebo, particularly given the high unmet need in antihistamine-refractory CSU.
- Regulatory Pathway
- The speed of the BLA submission and subsequent approval will depend on the Phase 3 data and Celldex’s interactions with regulatory agencies, potentially influencing the commercial launch timeline.
- Market Adoption
- How quickly physicians and patients adopt barzolvolimab, if approved, will be influenced by its perceived efficacy and safety profile relative to existing therapies like omalizumab, and its pricing strategy.
Related topics